NEW YORK, February 25, 2013 /PRNewswire/ --
Today, Investors Alliance announced new research reports highlighting Varian Medical Systems, Inc. (NYSE: VAR), Boston Scientific Corporation (NYSE: BSX), Stryker Corporation (NYSE: SYK), St. Jude Medical, Inc. (NYSE: STJ) and Thermo Fischer Scientific Inc. (NYSE: TMO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Varian Medical Systems, Inc. Research Report
World leader in radiotherapy and radiosurgery, Varian Medical Systems, has recently announced collaborating with key development agencies in Russia. This is to encourage the country's top scientific heads and research institutes to work on research and development proposals for programs aimed at advancing radiotherapy technology. The program presents the Russian R&D community with the opportunity to take a focused look at the needs of radiotherapy. "We believe this will yield significant benefits to cancer patients not only in Russia but throughout the world. Russia was the first country to put a man into space and it has a deep, sophisticated technological base in radiation technologies," says Scott Johnson , Varian's Senior Manager - Research Collaborations. The company has contributed $50,000 for this venture, which will be combined with other funds equaling $100K in prize money for the team or teams with the best proposals. Varian has more than 30 medical linear accelerators installed in Russian cancer clinics. The company currently provides up to 20 new treatment systems each year to radiotherapy departments in the country. The Full Research Report on Varian Medical Systems, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/f40b_VAR]
Boston Scientific Corporation Research Report
Innovation is at the core of everything that they do at Boston Scientific. As a developer, manufacturer and marketer of medical devices that are used in interventional medical specialties, the company continues to seek ways to grow. Despite a challenging 2012, CEO Mike Mahoney expects the market to stabilize this year. With trends moving in the company's favor, such as an expanding product line and strong emerging markets overseas, help offset slower growth in the US and other advanced countries. Boston Scientific has also been revamping both its management and commercial structure in response to the changes that are changing the health care industry worldwide. The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/b465_BSX]
Stryker Corporation Research Report
Stryker dedicates itself to helping healthcare professionals do their jobs more efficiently while enhancing patient care. It offers a diverse array of innovative medical technologies, that include reconstructive, medical and surgical, and neurotechnology and spine products to help people lead more active and more satisfying lives. Its recent undertakings include the development of smart beds. These beds communicate with health care communications systems, leading to better monitoring and increased levels of patient comfort during recovery. The Full Research Report on Stryker Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/8335_SYK]
St. Jude Medical, Inc. Research Report
EnligHTNment trail - a landmark study of renal denervation for reduction of heart attack, stroke and death - was initiated by St. Jude Medical. This study will examine whether renal denervation and medication can provide health benefits to patients beyond lowering high blood pressure. "To date, the renal denervation studies that have been conducted only looked at reducing blood pressure in patients with uncontrolled or resistant hypertension," said Professor Michael Bohm, director and chief of internal medicine and cardiology at the University of Saarland in Homburg/Saar, Germany, a principal investigator for the trial. The EnligHTNment trial will be an international, multi-center, randomized, controlled study examining the safety and effectiveness of renal denervation with the EnligHTN Renal Denervation System in reducing risk of major cardiovascular events. The Full Research Report on St. Jude Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/d3fb_STJ]
Thermo Fischer Scientific Inc. Research Report
Thermo Fischer launches the SureTect PCR system - a system that delivers test efficiencies for food safety laboratories that are testing for the most common bacterial pathogens. This combines a real-time PCR instrument with bespoke software and convenient pre-filled reagent components that together with a single PCR protocol for a range of common targets and samples types, thus streamlining the process. Results for all targets and matrix types can now be obtained in less than 24 hours. This enables food testing labs an easy set-up and result reading. The Full Research Report on Thermo Fischer Scientific Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/ce54_TMO]
Consider Investors Alliance
Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.
Contact: Patricia Byers
Copyright©2012 PR Newswire.
All rights reserved